Virology & Infectious Diseases RFP Opportunities
Gilead Sciences funds research on HIV, viral hepatitis, and fungal diseases to advance prevention, integrated care, and health equity through competitive RFPs.
Funder: Gilead Sciences
Due Dates: January 30, 2026 (INCLUSION Global LOI) | April 3, 2026 (INCLUSION Global Full Application) | May 4, 2026 (RESONATE LOI) | May 29, 2026 (RESONATE Full Application) | July 12, 2026 (GATHER AND LISTEN LOI)
Funding Amounts: INCLUSION Global: up to $5,000,000 total, typical projects ≤$500,000; RESONATE: up to $4,000,000 total; overhead capped at 30%; project durations generally up to 18–24 months.
Summary: Supports research on HIV, viral hepatitis, and fungal diseases to advance prevention, care integration, and health equity through competitive RFPs.
Key Information: Most programs require a Letter of Intent (LOI) before full application; eligibility and focus vary by RFP.
Description
Gilead Sciences offers a series of competitive Request for Proposal (RFP) programs to fund research in virology and infectious diseases, with a focus on HIV, viral hepatitis (B, C, D), and invasive fungal diseases. These opportunities are designed to support implementation research, clinical and community decision-making, and development of integrated care models. The RFPs aim to address unmet needs such as optimizing prevention strategies, improving equitable access and outcomes, advancing patient-centered care, and responding to evolving epidemiology and resistance profiles. Funding is awarded based on scientific merit, alignment with program goals, and potential to generate high-quality evidence to impact clinical decision-making and patient care.
